Latham & Watkins represented the initial purchasers in the offering while Cooley advised Cytokinetics.Cytokinetics, Incorporated, a late-stage biopharmaceutical company, has announced the pricing of its offering…
Cytokinetics’ $540 Million Convertible Senior Notes Offering
